Fig. 7
Neutrophil iOvaFla expression is sufficient for inflammatory disease. a Weight and tibiotarsal joint swelling as iOvaFla; MRP8-Cre−/− and iOvaFla; MRP8-Cre+/− mice age (n = 6 biological replicates per genotype). b Serum cytokines measured by a BD Biosciences cytokine bead array and IL-18 ELISA of 10–12-week-old mice. c Flow cytometry and d quantification of monocytes (MO; CD11b+ Ly6CHi Ly6GLo) and neutrophils (NE; CD11b+ Ly6CLo Ly6GHi). For each flow cytometry plot, the top row is from the spleen and the second row from peripheral and mesenteric lymph nodes. Each column represents a different genotype. e Weight and tibiotarsal joint measurements after OVA-Fla; MRP8-Cre+/− mice were administered either anti-IL-1R blocking antibody or isotype control every 3–4 days for 2 weeks (n = 3 biological replicates per treatment). Data in b–d are representative of three independent experiments. Error bars are s.d. Results were analysed with either a Mann–Whitney test or two-way ANOVA and Bonferroni post-tests; *p < 0.05, **p < 0.01, ***p < 0.001
